A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
Phase
3Span
97 weeksSponsor
Walvax Biotechnology Co., Ltd.Cancun
Recruiting
Healthy Volunteers
1-1 of 1